Jurgi Camblong Sells 12,232 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• CEO Jurgi Camblong sold 12,232 shares on April 10 at an average price of $4.72 (about $57,735) under a pre-arranged Rule 10b5-1 plan to cover tax withholding from vested awards, leaving him with 3,711,968 shares (a 0.33% reduction), and he made several additional small sales between March 19 and April 13.
• SOPHiA GENETICS stock traded around $4.96 (up 2.3%) with a market cap of roughly $340M, reported a -$0.28 EPS last quarter and negative net margin of 44.2%, and carries an average analyst rating of "Hold" with a $7.00 target (two Buys, one Sell).

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CEO Jurgi Camblong sold 12,232 shares of the business's stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.72, for a total transaction of $57,735.04. Following the transaction, the chief executive officer owned 3,711,968 shares in the company, valued at $17,520,488.96. The trade was a 0.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total transaction of $20,939.24.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total transaction of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.77, for a total transaction of $21,398.22.

SOPHiA GENETICS Stock Up 2.3%

Shares of SOPHiA GENETICS stock traded up $0.11 during trading on Tuesday, reaching $4.96. 148,768 shares of the company traded hands, compared to its average volume of 183,135. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70. The company has a 50 day moving average price of $4.74 and a 200-day moving average price of $4.71. The firm has a market capitalization of $339.71 million, a PE ratio of -9.73 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The business had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. As a group, equities research analysts expect that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

Institutional investors have recently made changes to their positions in the company. Savvy Advisors Inc. bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth $48,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth $49,000. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 4th quarter worth $49,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS in the 4th quarter worth $54,000. Finally, XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS in the 4th quarter worth $55,000. Institutional investors own 31.59% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. BTIG Research restated a "buy" rating and set a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Finally, Guggenheim boosted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.